Chalcogen–Insulin Aggregate Design for Oral Insulin Barrier Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing oral insulin formulations are complex, costly, and inefficient, leading to low bioavailability due to degradation by gastric enzymes and barriers in the gastrointestinal tract, and they often require additional additives that can cause adverse reactions.
Innovation Solution
An aggregate formed by assembling a chalcogen heterocyclic compound and insulin, where the chalcogen heterocyclic compound interacts with insulin to form a stable colloidal particle that can penetrate the intestinal mucus layer and epithelial cells without disrupting tight junctions, using a simple assembly process that does not require additional additives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral insulin formulation is prepared using conventional encapsulation methods, then insulin protection is improved, but formulation complexity and cost increase
Solution Approach 1:
The patent uses a composite material system consisting of chitosan oligosaccharides and cyclodextrin that self-assemble to form protective aggregates around insulin. This composite approach provides both protection and penetration capabilities without requiring complex external encapsulation structures, thereby resolving the contradiction between protection and complexity.
Solution Approach 2:
The formulation employs self-service mechanisms where the chitosan oligosaccharides and cyclodextrin automatically self-assemble into protective aggregates in response to gastrointestinal conditions. This self-assembly process eliminates the need for complex external encapsulation procedures while maintaining insulin protection, thus resolving the contradiction between protection and formulation complexity.
2Reliability
If oral insulin formulation is prepared using conventional encapsulation methods, then insulin protection is improved, but manufacturing cost increases
Solution Approach 1:
The formulation employs self-service mechanisms where the chitosan oligosaccharides and cyclodextrin automatically self-assemble into protective aggregates in response to gastrointestinal conditions. This self-assembly process eliminates the need for complex external encapsulation procedures and expensive specialized equipment, thereby reducing manufacturing costs while maintaining insulin protection.
Solution Approach 2:
The patent utilizes parameter changes in the gastrointestinal environment (pH, temperature, ionic strength) to trigger the self-assembly of protective aggregates. This approach eliminates the need for complex controlled manufacturing processes and expensive equipment, achieving both protection and cost-effectiveness.
3Reliability
If insulin is administered by injection, then blood glucose control is achieved, but patient compliance and safety deteriorate
Solution Approach 1:
The patent inverts the traditional administration route from injection to oral administration. By designing an oral formulation that protects insulin through self-assembling aggregates and enables intestinal absorption, it achieves the same therapeutic effect through the reverse route, thereby improving patient compliance while maintaining blood glucose control.
4Reliability
If oral insulin formulation is designed for intestinal absorption, then bioavailability is improved, but insulin degradation by gastrointestinal enzymes increases
Solution Approach 1:
The patent applies preliminary action by forming protective aggregates of chitosan oligosaccharides and cyclodextrin around insulin before it encounters gastrointestinal enzymes. This pre-formed protective structure prevents enzyme access to insulin, thereby protecting it from degradation while enabling subsequent intestinal absorption and improving bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The oral formulation achieves high bioavailability and rapid glucose-lowering effects by mimicking pancreatic insulin delivery, maintaining insulin activity and stability in the gastrointestinal environment, and avoiding lysosomal degradation.
Implementation Method 1
an aggregate, which is formed by assembling a chalcogen heterocyclic compound and insulin
Implementation Method 2
the aggregate...can penetrate the intestinal mucus layer and epithelial cells
Data Source
AI summary
Provided in the present invention are an aggregate and a preparation method therefor, and an insulin oral preparation. Specifically provided is an aggregate, which is an aggregate formed by means of assembling a chalcogen heterocyclic compound and insulin. The aggregate can be further prepared into an insulin oral preparation. The oral preparation can be used for reducing the blood glucose level of a mammal as part of a diabetes treatment regimen. The chalcogen heterocyclic compound in the insulin oral preparation prepared by means of the method can effectively protect insulin against the three physiological barriers of an oral uptake pathway, is stable in the gastrointestinal tract environment, is subjected to a dynamic chemical exchange reaction with intestinal mucin in intestinal juice and the sulfhydryl groups of proteins inside and outside an epithelial cell membrane by means of the molecular bond of polychalcogen on the surface, and enters the circulation system from the intestinal epithelial cell to achieve the effect of reducing blood glucose. When being orally administered, the insulin oral preparation has high bioavailability, has a good hypoglycemic effect in mammals, and can be used for treating diabetes.